The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Metabolites. 2022 Mar 11;12(3):238. doi: 10.3390/metabo12030238.
Ryan D Welch1, Cyrielle Billon2, McKenna Losby3, Gonzalo Bedia-Diaz2, Yuanying Fang2, Amer Avdagic2, Bahaa Elgendy24, Thomas P Burris5, Kristine Griffett6
Author information
Biology and Chemistry Department, Blackburn College, Carlinville, IL 62626, USA.
Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University in St. Louis, St. Louis, MO 63110, USA.
Biochemistry, Biophysics and Structural Biology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
Department of Anesthesiology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
UF Genetics Institute, University of Florida, Gainesville, FL 32611, USA.
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Abstract
Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptors and their biology has promoted the development of synthetic ligands. The possibility of targeting these receptors to treat NAFLD is promising, as several compounds including Cilofexor, thiazolidinediones, and Saroglitazar are currently undergoing clinical trials. This review focuses on the latest development of the pharmacology of these metabolic nuclear receptors and how they may be utilized to treat NAFLD and subsequent comorbidities.